Coherus Oncology, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CHRS | CGEN | HURA | PYXS | CRVS | HBP.TO | |
|---|---|---|---|---|---|---|
| Market cap | 131.36M | 192.29M | 109.61M | 198.30M | 889.16M | 70.27M |
| P/E (TTM) | — | 5.3 | — | — | — | — |
| Forward P/E | -1.3 | -5.5 | -2.8 | -1.5 | -9.9 | -8.4 |
| Price/book | 2.2 | 2.2 | 6.0 | 9.2 | 3.9 | 4.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −42.95% | +23.78% | −29.80% | −58.91% | +35.17% | −54.68% |
| Today | +5.54% | +1.00% | +3.93% | +1.22% | +7.53% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CHRS news ›Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer - Slideshow
2026-11-02. The following slide deck was published by Coherus Oncology, Inc. The following slide deck was published by Coherus Oncology, Inc. in conjunction with this event.
Coherus Oncology, Inc. (NASDAQ:CHRS) Sees Significant Decline in Short Interest
Posted by Sarita Garza on Oct 31st, 2026 Check Out Our Latest Analysis on Coherus Oncology Here are the key news stories impacting Coherus Oncology this week: Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage…
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release inte... Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October…
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that it has initiated the proces... Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets REDWOOD CITY,…
Coherus to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be partici... Coherus to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Aug. 31, 2026…
Zymeworks (NASDAQ:ZYME) versus Coherus Oncology (NASDAQ:CHRS) Financial Review
Posted by Mitch Edgeman on Oct 28th, 2026 Zymeworks (NASDAQ:ZYME – Get Free Report) and Coherus Oncology (NASDAQ:CHRS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based…
HUTCHMED sets Nov. 5 savolitinib data webcast
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Elong Power Holding Limited (NASDAQ: ELPW) Announces Subsidiary’s Entry into a US$25.5 Million Annual Cooperation Agreement,…
Corbus CRB-701: 42.9% response in oropharyngeal cancer
Alpha Modus Signs ARIA Beta Agreement with Greer’s Markets Corbus lists a potential CRB-701 BLA filing for second-line OPSCC in the second half of 2028. Date of Report (Date of earliest event reported): October 15, 2026 (Exact name of…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com5
- stocktitan.net3
- themarketsdaily.com2
- quiverquant.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.